Moderna's mRNA vaccine for RSV appears to be safe and effective in older adults

Embargoed until: Publicly released: 2023-12-14 09:01

International

What does this mean?

Jump to: MultimediaAttachmentsExpert Reaction

A gold standard clinical trial of Moderna's mRNA-1345 vaccine for respiratory syncytial virus (RSV) in more than 35,000 adults aged 60 or over found the vaccine was 83.7% effective against RSV-associated lower respiratory tract disease with at least two signs or symptoms, 82.4% effective against the disease with at least three signs or symptoms, and 68.4% effective against serious respiratory disease. Most adverse reactions were mild and short-lived. Serious adverse events were reported in 2.8% of people in the group given the vaccine and also in the group given a non-active placebo jab.